All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The survival outcomes for patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) are poor; therefore, there is a need for novel targeted therapies in this patient population.
Here, we summarize preliminary results of a phase I trial (EudraCT:2021-004312-25) evaluating the efficacy and safety of CD7-directed chimeric antigen receptor (CAR) T-cell therapy in children with R/R T-cell ALL, presented by Chiesa at the 50th Annual Meeting of the EBMT.
This was an open-label, single-center phase I study including patients aged 6 months to 16 years with R/R CD7+ (>99%) T-cell malignancies and bone marrow involvement who were eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Figure 1. Treatment schema*
Allo-HSCT, allogeneic hematopoietic stem cell transplantation; BM, bone marrow; CAR, chimeric antigen receptor; MRD, minimal residual disease.
*Data from Chiesa.1
†Dose: 0.2−2.0 × 106 per kilogram; max: 5 × 104 per kilogram TCRαβ T cells
Figure 2. Outcomes of CD7-directed CAR T-cells in children with R/R T-ALL*
CAR, chimeric antigen receptor; CMV, cytomegalovirus; CNS, central nervous system; CR, complete remission; HSCT, hematopoietic stem cell transplantation; ICANS, immune effector cell-associated neurotoxicity syndrome; IR, immune reconstitution; MRD, minimal residual disease; PCR, polymerase chain reaction; T-ALL, T-cell acute lymphoblastic leukemia.
*Data from Chiesa.1
Key learnings |
|
Subscribe to get the best content related to ALL delivered to your inbox